AFP
CRSP icon

Ausdal Financial Partners’s CRISPR Therapeutics CRSP Stock Holding History

Ausdal Financial Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,862
Closed -$231K – 1056
2026
Q1 		$231K Buy
4,862
+52
+1% +$2.74K 0.01% 881
2025
Q4 		$252K Sell
4,810
-309
-6% -$18.5K 0.01% 813
2025
Q3 		$332K Buy
+5,119
New +$294K 0.02% 691

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ausdal Financial Partners's CRSP Position: Q2 2026 in Review

Ausdal Financial Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 4,862 shares — an estimated $231K sold.

Ausdal Financial Partners first reported a position in CRSP in Q3 2025 and held it in 3 quarters. The position peaked at $332K in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Ausdal Financial Partners reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ausdal Financial Partners sold 4,862 CRISPR Therapeutics shares in Q2 2026, an estimated $231K.
  • Ausdal Financial Partners first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 3 quarters.
  • Ausdal Financial Partners's CRISPR Therapeutics position peaked at $332K in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Ausdal Financial Partners's 13F filing for Q2 2026, filed 14 Aug 2026.